John Sory adds, “ERT’s industry-leading technology and solutions, which have driven its success in the cardiac safety area of clinical trials, can be leveraged in unique ways for the health care market and in other areas of clinical trials. I am delighted to lead the path toward this goal. In this time of intensive health reform, we have an opportunity to bring established competencies to the market in exciting new ways.We look forward to developing our strategy, that will allow us to build, partner, pilot and launch a number of meaningful and innovative products and services.”

For further information on ERT and its technology and services, please email info@ERT.com, call +1215-972-0420 or visit www.ERT.com.

For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44-1477-539-539, Fax +44-1477-539-540, email ert@scottpr.co.uk

About ERT

Based in Philadelphia, PA ERT (eResearchTechnology, Inc.) (www.ERT.com) is a global provider of technology and services to the biopharmaceutical, medical device, and related industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company’s ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.